NCT00507416 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 168
- group Id
- BG001
- value
- 167
- group Id
- BG002
- value
- 167
- group Id
- BG003
- value
- 502
- units
- Participants
- groups
- description
- Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
- id
- BG000
- title
- Bortezomib and Dexamethasone
- description
- Participants received bortezomib 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
- id
- BG001
- title
- Bortezomib, Thalidomide, and Dexamethasone
- description
- Participants received bortezomib 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
- id
- BG002
- title
- Bortezomib, Melphalan and Prednisone
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.35
- value
- 72.6
- group Id
- BG001
- spread
- 8.73
- value
- 71.3
- group Id
- BG002
- spread
- 8.67
- value
- 71.3
- group Id
- BG003
- spread
- 8.92
- value
- 71.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 140
- group Id
- BG001
- value
- 135
- group Id
- BG002
- value
- 139
- group Id
- BG003
- value
- 414
- title
- ≥ 65 years
- categories
- measurements
- group Id
- BG000
- value
- 84
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 62
- group Id
- BG003
- value
- 210
- title
- ≥ 75 years
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 90
- title
- ≥ 80 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 67
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 77
- group Id
- BG003
- value
- 241
- title
- Female
- measurements
- group Id
- BG000
- value
- 101
- group Id
- BG001
- value
- 70
- group Id
- BG002
- value
- 90
- group Id
- BG003
- value
- 261
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 131
- group Id
- BG001
- value
- 124
- group Id
- BG002
- value
- 118
- group Id
- BG003
- value
- 373
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 83
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- American Indian or Alaskan Native
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 35
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Not Reported
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 168
- group Id
- BG001
- value
- 167
- group Id
- BG002
- value
- 167
- group Id
- BG003
- value
- 502
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- Intention to treat population, defined as all participants randomized
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 168
- group Id
- BG001
- value
- 167
- group Id
- BG002
- value
- 167
- group Id
- BG003
- value
- 502
- units
- Participants
- groups
- description
- Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
- id
- BG000
- title
- Bortezomib and Dexamethasone
- description
- Participants received bortezomib 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
- id
- BG001
- title
- Bortezomib, Thalidomide, and Dexamethasone
- description
- Participants received bortezomib 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
- id
- BG002
- title
- Bortezomib, Melphalan and Prednisone
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.35
- value
- 72.6
- group Id
- BG001
- spread
- 8.73
- value
- 71.3
- group Id
- BG002
- spread
- 8.67
- value
- 71.3
- group Id
- BG003
- spread
- 8.92
- value
- 71.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 140
- group Id
- BG001
- value
- 135
- group Id
- BG002
- value
- 139
- group Id
- BG003
- value
- 414
- title
- ≥ 65 years
- categories
- measurements
- group Id
- BG000
- value
- 84
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 62
- group Id
- BG003
- value
- 210
- title
- ≥ 75 years
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 90
- title
- ≥ 80 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 67
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 77
- group Id
- BG003
- value
- 241
- title
- Female
- measurements
- group Id
- BG000
- value
- 101
- group Id
- BG001
- value
- 70
- group Id
- BG002
- value
- 90
- group Id
- BG003
- value
- 261
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 131
- group Id
- BG001
- value
- 124
- group Id
- BG002
- value
- 118
- group Id
- BG003
- value
- 373
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 83
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- American Indian or Alaskan Native
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 35
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Not Reported
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 168
- group Id
- BG001
- value
- 167
- group Id
- BG002
- value
- 167
- group Id
- BG003
- value
- 502
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- Intention to treat population, defined as all participants randomized
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle